Previous 10 | Next 10 |
Galmed Announces New Positive Data from Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect on Fibrosis Improvement PR Newswire -- Updated liver histology data from first 20 patients show 60% fibrosis improvement by at least 1 stage as...
Galmed Pharmaceuticals (GLMD +1.6%) announces results from the first 16 patients in the Open-Label Part of the ARMOR Phase 3 study of Aramchol in patients with NASH and liver fibrosis. Treatment with Aramchol reduced fibrosis progression in 15 out of the 16 patients. 8 out of the 16 pati...
Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study -- Treatment with Aramchol 300mg BID reduced fibrosis progression measured by histology in 15 out of the 16 patients completed as of data cutoff -- -- 50% of the 16 patients showed fib...
Results of Galmed's Phase 2b ARREST Trial of Aramchol Published in Nature Medicine - Data add to the growing body of clinical and scientific evidence demonstrating the therapeutic potential of Aramchol, a stearoyl CoA desaturase (SCD 1) down regulator, for the treatment of NASH ...
Galmed Pharmaceuticals Announces Publication in "The Journal of Autoimmunity" for its IND ready, Amilo-5MER, a specific anti-inflammatory compound - Amilo-5MER suppresses chronic inflammations in broad spectrum of animal models of inflammatory diseases. - Amilo-5MER has a un...
MHRA Agrees with Galmed's Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR study - MHRA agreement follows similar agreement from the FDA which allows Galmed to proceed with its proposed clinical studies with Aramchol megl...
Galmed Pharmaceuticals Ltd. (GLMD) Q2 2021 Results Earnings Conference Call August 05, 2021, 8:30 am ET Company Participants Allen Baharaff - President, Chief Executive Officer Yohai Stenzler - Chief Financial Officer Liat Hayardeny - Chief Scientific Officer Conference Call Participants Edwa...
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results - Conference Call and Webcast Today at 8:30 a.m. ET / 5:30 a.m. PT - PR Newswire TEL AVIV, Israel , Aug. 5, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nas...
Hancock Jaffe Laboratories HJLI +40% on Breakthrough Device tag for VenoValve Wilhelmina International (NASDAQ:WHLM) +36%. Outlook Therapeutics OTLK +35% on late-stage wet AMD bevacizumab study results Translate Bio TBIO +29% Sanofi to acquire Translate Bio for $...
Gainers: Ever-Glory International Group (NASDAQ:EVK) +122%. Infinity Pharmaceuticals (NASDAQ:INFI) +33%. Exicure (NASDAQ:XCUR) +34%. Xenetic Biosciences (NASDAQ:XBIO) +31%. Atlas Technical Consultants (NASDAQ:ATCX) +28%. Annovis Bio (NYSE:ANVS) +22%. Full Truck Alliance (NYSE:YMM) +21%. Allie...
News, Short Squeeze, Breakout and More Instantly...
Galmed Pharmaceuticals Ltd. Company Name:
GLMD Stock Symbol:
NASDAQ Market:
Galmed Pharmaceuticals Ltd. Website: